1. Executive Summary
2. United States Influenza Vaccines Market Size and Forecasts (2015 – 2028)
3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2028)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Restraints
5. United States Influenza Vaccines Pricing Trends & Analysis
6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
7. United States Influenza Vaccines Distribution & Demand (2010 – 2021)
8. Effectiveness of Influenza Vaccines in the United States (2004 – 2021)
9. Rapid Diagnostic Testing for the Management of Influenza
10. Distribution Channel and Technique of Influenza Vaccination in the United States
11. Reimbursement Environment of the United States Influenza Vaccines Market
12. Regulatory Framework of the United States Influenza Vaccines Market
13. Major Deals and Agreement Happenings in the Influenza Vaccines Market
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. Promising Influenza Vaccines in the Clinical Development
15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
15.1 Year 2020
15.2 Year 2019
16. Key Players Analysis
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. Emerging Players
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Vaccines in the Clinical Development
17.9.3 Recent Development
17.10 EpiVax
17.10.1 Business Overview
17.10.2 Promising Influenza Vaccines in the Clinical Development
17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc
17.11.1 Business Overview
17.11.2 Promising Influenza Vaccines in the Clinical Development
17.11.3 Recent Development
Table 5–1: United States Pediatric Influenza Vaccines Price, 2021 – 2022
Table 5–2: United States Adult Influenza Vaccine Price, 2021 – 2022
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 7–2: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–7: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 13–2: Collaboration Deal in the Influenza Vaccines Market
Table 13–3: Licensing Agreement in the Influenza Vaccines Market
Table 13–4: Exclusive Agreement in the Influenza Vaccines Market
Table 13–5: Distribution Agreement in the Influenza Vaccines Market
Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:
Figure 2–1: United States Influenza Vaccines Market (Million US$),2015 – 2020
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2021 – 2028
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2028
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2028
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2028
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2021
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 – 2020
Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer